Unilens Vision Inc, based in Largo, FL, announced they have entered into an agreement with a subsidiary of Valeant Pharmaceuticals, for the acquisition of all common stock at a value of $28 million. The deal is expected to close September 1, 2015. Unilens provides a line of specialty lens products to the eye care professionals under the C-Vue® brand name and market and sell products directly to eye care professionals.
Michael J. Pecora, Chairman of the Board, Chief Executive Officer and President of Unilens, stated, “We are very pleased to sign a definitive agreement with Valeant, which creates immediate value for our stockholders. The combination of Unilens’ world class technology and its leading customized lens business with Valeant will create a strong portfolio of products enhancing our commitment to providing the best possible visual outcomes throughout the optical industry.”
The news release does not mention with which subsidiary of Valeant the agreement has been made. Valeant Pharmaceuticals, headquartered in Laval, QC, completed its acquisition of Bausch + Lomb in 2013, and integrated Valeant’s existing ophthalmology businesses to create a global eye health platform.
Source:
